MARKET

OPK

OPK

Opko Health
NASDAQ
1.350
-0.030
-2.17%
After Hours: 1.350 0 0.00% 19:58 07/18 EDT
OPEN
1.380
PREV CLOSE
1.380
HIGH
1.390
LOW
1.340
VOLUME
2.57M
TURNOVER
--
52 WEEK HIGH
2.035
52 WEEK LOW
1.210
MARKET CAP
1.07B
P/E (TTM)
-22.8814
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at OPK last week (0707-0711)?
Weekly Report · 5d ago
Opko Health (OPK) Has a New Rating from Ladenburg Thalmann & Co.
TipRanks · 07/10 17:25
Weekly Report: what happened at OPK last week (0630-0704)?
Weekly Report · 07/07 09:12
NextPlat Interim CEO Issues Shareholder Letter Outlining Strategic Vision For Growth In Healthcare And E-Commerce
Benzinga · 06/30 12:08
Weekly Report: what happened at OPK last week (0623-0627)?
Weekly Report · 06/30 09:12
OPKO Health And Entera Bio Say New Pharmacologic And Pharmacokinetic In Vivo Data For Investigational Oral OPK-88006 Tablet Treatment Selected For Presentation At ENDO 2025 Annual Meeting
Benzinga · 06/25 12:12
Entera Bio, Opko Health announce new in vivo data for OPK-88006
TipRanks · 06/25 12:10
Opko Health, Entera Bio say OPK-88006 data selected for ENDO 2025
TipRanks · 06/25 12:10
More
About OPK
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

Webull offers OPKO Health Inc stock information, including NASDAQ: OPK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OPK stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OPK stock methods without spending real money on the virtual paper trading platform.